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Protein levels and function are poorly predicted by genomic and transcriptomic analysis of patient 
tumors. Therefore, direct study of the functional proteome has the potential to provide a wealth of 
information that complements and extends genomic, epigenomic and transcriptomic analysis in 
The Cancer Genome Atlas (TCGA) projects. Here we use reverse-phase protein arrays to analyze 
3,467 patient samples from 11 TCGA “Pan-Cancer” diseases, using 181 high-quality antibodies 
that target 128 total proteins and 53 post-translationally modified proteins. The resultant proteomic 
data is integrated with genomic and transcriptomic analyses of the same samples to identify 
commonalities, differences, emergent pathways and network biology within and across tumor 
lineages. In addition, tissue-specific signals are reduced computationally to enhance biomarker 
and target discovery spanning multiple tumor lineages. This integrative analysis, with an emphasis 
on pathways and potentially actionable proteins, provides a framework for determining the 
prognostic, predictive and therapeutic relevance of the functional proteome.
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Introduction
The Cancer Genome Atlas (TCGA) is generating comprehensive molecular profiles for each 
of at least 33 different human tumor types (http://cancergenome.nih.gov). The overarching 
goal is to elucidate the landscape of DNA and RNA aberrations within and across tumor 
lineages and integrate the information with clinical characteristics, including patient 
outcome.
Previous studies have indicated only a partial concordance between genomic copy number, 
RNA levels and protein levels in both patient samples and cell lines1, 2, 3 at least, in part, 
because protein levels and, in particular, phosphoprotein levels represent an integration of 
the complex genomic and transcriptomic aberrations accumulated in each tumor combined 
with translational and post-translational regulation that cannot be fully captured by genomic 
and transcriptomic analysis. Hence, functional protein analysis using reverse-phase protein 
arrays (RPPA), which are highly applicable to study the large numbers of TCGA samples, 
was added to the TCGA effort to integrate proteomic characterization of tumors with already 
available genomic, transcriptomic and clinical information. The Clinical Proteomic Tumor 
Analysis Consortium (CPTAC, http://proteomics.cancer.gov/programs/cptacnetwork) is 
starting to use mass spectrometry to analyze a large fraction of the human proteome for a 
select subset of TCGA tumors. However, a comprehensive mass spectrometry analysis 
across all TCGA samples is not likely to be available in the near future. Thus, while earlier 
TCGA analyses were primarily based on genomic and transcriptomic 
characteristics4, 5, 6, 7, 8, 9, 10, the current study is driven by proteomic processes within and 
across cancer types.
Here we report an RPPA-based proteomic analysis using 181 high-quality antibodies that 
target total (n=128), cleaved (n=1), acetylated (n=1) and phosphorylated forms (n=51) of 
proteins in 3,467 TCGA patient samples across 11 “Pan-Cancer” tumor types. The function 
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space covered by the antibodies used in the RPPA analysis includes proliferation, DNA 
damage, polarity, vesicle function, EMT, invasiveness, hormone signaling, apoptosis, 
metabolism, immunological, and stromal function as well as transmembrane receptors, 
integrin, TGFβ, LKB1/AMPK, TSC/mTOR, PI3K/Akt, Ras/MAPK, Hippo, Notch, and 
Wnt/beta-catenin signaling. Thus, the function space encompasses major functional and 
signaling pathways of relevance to human cancer. The TCGA tumor types included are 
those with mature RPPA data: breast cancer (BRCA, n=747), colon (COAD, n=334) and 
rectal (READ, n=130) adenocarcinoma, renal clear cell carcinoma (KIRC, n=454), high-
grade serous ovarian cystadenocarcinoma (OVCA, n=412), uterine corpus endometrial 
carcinoma (UCEC, n=404), lung adenocarcinoma (LUAD, n=237), head and neck squamous 
cell carcinoma (HNSC, n=212), lung squamous cell carcinoma (LUSC, n=195), bladder 
urothelial carcinoma (BLCA, n=127) and glioblastoma multiforme (GBM, 
n=215) 4, 5, 6, 7, 8, 9, 10. We show that the functional proteome gives important, independent 
insights in TCGA data that are not captured by genomics or transcriptomics. Although 
samples predominantly cluster by tumor lineage, we also show that part of the tissue 
dominant effects can be removed computationally to elucidate common processes driving 
cellular behavior across tumor lineages. We present proteins and pathways that correlate 
with outcomes within certain tumor lineages and we identify multiple protein links and 
proteins that are associated with pathway activation. Taken together, the data and analytical 
resources presented in this manuscript are aimed at facilitating future research for targeted 
therapies that span multiple tumors.
Results
Correlations between protein and other data types
Protein data for 3,467 samples across 11 diseases were compared to mRNA, miRNA, copy 
number, and mutation data for the same samples. A novel approach, called “replicates-based 
normalization” (RBN, Methods), mitigated batch effects facilitating creation of a single Pan-
Cancer protein dataset merging samples across 6 different batches. The RBN output is 
equivalent to all 3,467 samples being run in a single batch. In contrast to random (trans) 
protein:mRNA pairs (mean Spearman’s ρ = −0.006), almost half of matched (cis) 
protein:mRNA pairs in the RBN set demonstrated correlation beyond that expected by 
chance (mean Spearman’s ρ = 0.3) in both the overall Pan-Cancer dataset (t-test P < 2.2e-16, 
n=206 matched protein:mRNA pairs) and within particular diseases (Fig. 1a, Supplementary 
Fig. 1, Supplementary Data 1,2). Approximately 44% of matched (cis) protein:mRNA pairs 
had a correlation >= 0.3. For micro-RNAs, as expected, (trans) protein:miRNA correlations 
were much weaker with a mean positive Spearman’s ρ = 0.07, and a mean negative 
Spearman’s ρ = −0.07 (Supplementary Data 3). On the other hand, (trans) protein:protein 
correlations, including phosphoproteins, were higher (mean positive Spearman’s ρ = 0.15, 
mean negative Spearman’s ρ = −0.13, Supplementary Data 4). Detailed protein:protein and 
phosphoprotein:protein correlations across the total dataset and in particular diseases are 
available at the TCPA portal11. The results show, not surprisingly, that matched (cis) 
mRNA:protein correlations were the highest on average (ρ = 0.3), followed by (trans) 
protein:protein correlations (ρ ≈ ±0.15), whereas (trans) protein:miRNA correlations were 
lowest on average (ρ = ±0.07).
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A similar analysis for CNV vs. protein fold change showed a mean fold change of 1.05 for 
amplifications and 0.95 for deletions in cis (Supplementary Data 5,6). Mutation vs. protein 
(cis) analysis showed a mean fold change of 1.2 for mutations that increased expression, and 
0.9 for mutations that decreased expression (Supplementary Data 7,8), showing that 
mutations, in general, are associated with greater average fold changes than copy number 
variations, perhaps due to nonsense mediated RNA degradation. Complete tables are 
available at: (http://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
HER2 analysis as an example
We then focused on HER2 as an illustrative example. A comparison of relative HER2 
(ERBB2) protein levels across tumor types illustrates the potential utility of a pan-cancer 
proteomic analysis. While the overall HER2 protein:mRNA correlation was 0.53 (P = 
5e-177), the correlation was 0.61 (P = 1e-69) in BRCA, where HER2-targeted therapy has 
been demonstrated to be effective (Spearman’s correlations Fig. 1, Supplementary Data 1). 
Importantly, phosphoHER2Y1248 protein:mRNA correlation was 0.552 (P = 3e-54) and 
HER2:phosphoHER2Y1248 protein:protein correlation was 0.67 (P = 4e-98) in breast cancer 
consistent with ability of RPPA to capture both total and phosphoprotein levels from TCGA 
samples (n=2,503 for overall and n=674 for BRCA correlations and P-value computations 
using t-distribution test and adjusted for multiple hypotheses testing using Benjamini 
Hochberg adjustment. n=2,479 in Fig. 1). Based on correlations with DNA, RNA and 
protein levels in HER2-positive breast cancers, HER2 protein levels were defined as 
elevated if the relative HER2 level was ≥1.46 (see Methods) (Fig. 1b-d). We also set a cutoff 
at the relative protein level of 1.00 (which is roughly equivalent to 3+ staining on clinical 
immunohistochemistry analysis of the breast cancer samples and represent the top 12% of 
patient samples, see Methods). Using either cutoff, 10–15% of breast cancers demonstrated 
elevated HER2 by DNA copy number, RNA and protein consistent with clinical data12, 13 
(Fig. 1b). Based on those cutoffs, approximately 25% of serous endometrial cancers had 
coordinated elevation of HER2 DNA, RNA, and protein levels, an even higher frequency 
than breast cancer. BLCA, colorectal cancer and LUAD demonstrated a higher frequency of 
elevated protein levels than predicted by mRNA and DNA levels. In an independent cohort 
of 26 LUAD cell lines using the same cutoffs, 7 of the cell lines had high HER2 protein 
levels, whereas only 2 cell lines had high mRNA levels, consistent with our observation of 
elevated protein levels occurring at a higher frequency than elevated RNA levels 
(Supplementary Table 1, Supplementary Fig. 2)14.
Discordance between HER2 DNA copy number and protein levels has been observed in 
multiple individual tumors types previously15, 16, 17, 18, 19, 20. Besides diversity in 
methodology, a number of cancer specific hypotheses, including post-translational 
regulation of HER2 expression, cytoplasmic HER2 localization16, intratumoral 
heterogeneity of HER2 amplification19 or polysomy 1717, 20 have been suggested. This 
clearly contrasts breast cancer, where HER2 levels are usually highly correlated at the DNA, 
RNA and protein level21, 22, 23, 24. With the advent of TDM1 toxin conjugate therapy 
(trastuzumab emtansine)25, 26, the higher frequency of elevated HER2 protein levels in 
BLCA, LUAD, endometrial, and colorectal cancers supports the (pre)clinical exploration of 
TDM1, which binds HER2 to deliver a potent cell-cycle toxin (a mechanism of activity 
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independent from trastuzumab, a drug with limited activity in endometrial cancer in 
previous studies27) in these tumor lineages.
Unsupervised clustering analysis
Unsupervised clustering identified eight robust clusters (Clusters A-H, Fig. 2a) when batch 
effects were mitigated by RBN. Not surprisingly, RBN cluster membership is defined 
primarily by tumor type with the exception of cluster_E and cluster_F, which include 
multiple diseases (Fig. 2b). Bladder cancer, however, did not generate a dominant cluster 
but, rather, was co-located with other tumor lineages in multiple clusters. To identify 
potential discriminators of clusters, we compared the ability of proteins, RNAs, miRNAs 
and mutations for each cluster to different samples from those in all other clusters (top 25 
discriminators, Supplementary Tables 2-5, all the discriminators at http://
bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA). Supplementary Table 2 
highlights the contribution of individual proteins in driving the different clusters. 
Associations of specific mutations and copy number changes with the clusters were 
primarily based on known associations of mutations and copy number changes with tumor 
lineage.4, 5, 6, 7, 8, 9, 10
Cluster_E includes 70% of basal-like breast cancers, the majority of HER2 positive breast 
cancers (87%) and the largest group of bladder cancers (35%), including many with 
amplified HER2 (Fig. 2a,b). Cluster_E is defined by TP53 mutations, elevated HER2, 
cyclinB1 and Rab25 protein levels and low ER and PR levels (Supplementary Table 2). 
Cluster_F includes smoking-related, upper aerodigestive tract cancers (HNSC, LUAD, and 
LUSC) and subsets of other tumor types. Cluster_F contains the majority of a “squamous 
cancer” subset (94%), P<0.0001, Chi-squared test), recently identified through other Pan-
Cancer subtype analyses (Hoadley K, personal communication). However, cluster_F also 
contains an equally large number of non-squamous tumors, predominantly LUAD (58% of 
the non-squamous tumors in cluster_F). Membership in cluster_F is associated with TP53 
mutations and elevated total and phosphorylated EGFR (EGFRp1068 and EGFRp1173), 
phosphorylated SRC (SRCpY527) and low ER and PR levels. Although TP53 mutations are 
usually associated with copy number changes and a limited number of recurrent mutations in 
cancer genes7, cluster_F is unexpectedly enriched in recurrent cancer gene mutations 
(Supplementary Table 6). Within the group of current smokers in cluster_F (Supplementary 
Fig. 3), tumors with TP53 mutations show significantly higher rates of co-mutations in the 
top-25 driver mutations (Methods, P<0.0001, t-test, n=162).
Hormonally responsive ‘women’s cancers’ (luminal BRCA, OVCA, UCEC) form a major 
tumor super cluster. Basal-like breast cancers and HER2-positive breast cancers are distinct 
from luminal breast cancers, being located in cluster_E (the majority of HER2 (87%) and 
basal-like (70%)) and cluster_F (subset of basal-like (25%)). This is consistent with previous 
data suggesting that HER2 and basal-like breast cancer are distinct from luminal breast 
cancer5. In light of the recent identification of a “reactive” breast cancer subtype5, we split 
the luminal cluster into two (reactive breast cluster_A1 and non-reactive ER-positive breast 
cluster_A2).
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For some tumor lineages, localization to different clusters reflects differences in prognosis. 
Breast cancers located in different clusters demonstrate distinct outcomes: tumors in 
cluster_E and cluster_F are associated with the worst outcome, probably due to the inclusion 
of HER2-positive and basal-like tumors. Reactive cluster_A1 shows a better outcome than 
cluster_A2 (Fig. 2c). The poor outcome associated with KIRC in cluster_F (Fig. 2d) may be 
due to the absence of VHL mutations (Fisher's exact test (FE), P = 0.008, n=454), which has 
been associated with a worse outcome in kidney cancer28. Bladder cancers in cluster_B 
show worse survival compared to all other BLCA, which may be due to associations with 
TP53 mutation (FE, P<0.001) and cMYC amplification (FE, P = 0.042) (n=127) (Fig. 2e).
We evaluated the concordance between RBN protein clusters and mRNA clusters derived 
from the same sample set (Supplementary Table 7). Most of the protein clusters 
predominantly corresponded to a single respective mRNA cluster despite the mRNA clusters 
being defined with a pool of about 20,000 mRNAs, whereas only 181 proteins and 
phosphoproteins were used to generate the protein clusters. Therefore, many of the features 
defining the mRNA clusters were captured by just a few proteins. This agreement between 
RNA and protein based clustering provides validation of the quality of the protein data, as 
well as the selection of protein targets in the arrays. However, clusters E and F were 
noticeably different from their mRNA counterparts. Unlike protein cluster_E that contains 
BLCA and BRCA, bladder cancer formed a separate cluster in mRNA data, distinct from 
HER2 and basal-like breast cancers. LUAD also formed a separate mRNA cluster, distinct 
from the LUSC/HNSC mRNA cluster, unlike protein cluster_F that contains LUAD as well 
as LUSC and HNSC.
Reduction of tissue-specific proteomic signatures
Tumor lineage represents the dominant determinant of protein clustering using the RBN 
approach (Fig. 2). We, therefore, investigated whether further transforming the RBN data to 
reduce tissue signatures by median centering within tissue types (MC, see Methods) would 
identify clinically or biologically relevant protein patterns that span multiple tumor lineages 
(Fig. 3a). Using MC, we obtained 7 clusters (I-VII) that were no longer strongly correlated 
with tumor lineage, as evident from the top annotation bar in Fig. 3a (Supplementary Fig. 4), 
and from the tissue vs. cluster cross-tabulation (Fig. 3b). This allowed exploration of 
molecular events that spanned multiple tissues, which was not possible with the RBN 
approach. Supplementary Table 8 shows a contingency table the distribution of samples 
across RBN vs. MC clusters, highlighting the differences between the clusters. 
Supplementary Tables 9-12 show the top 25 proteins, mRNAs, miRNAs, and mutations that 
discriminated different MC clusters (full table available at http://
bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
Cluster_I was primarily driven by phosphoPEA15, YB1, EEF2 and ETS1 proteins 
(Supplementary Table 9), which were markedly elevated in a subset of colorectal tumors 
(18%). Cluster_I exhibited enrichment of APC and KRAS mutations, very few HER2 
amplifications, but moderately high HER2 protein levels (Fig. 3a, Supplementary Tables 
9,12). It also had evidence for suppressed DNA damage response, apoptosis, and mTOR and 
MAPK pathway levels (Fig. 4b). Cluster_II was divided into two further sub-clusters, one 
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primarily driven by HER2 (IIa) and one by EGFR (IIb) (Supplementary Table 9). 
Interestingly, a subset of OVCA, UCEC, BLCA and LUAD samples that had HER2 
amplification and HER2 protein levels comparable to breast HER2+ samples were located in 
cluster_IIa, raising intriguing opportunities for (pre)clinical investigation of HER2 targeted 
therapy and particularly TDM1 therapy as noted above. Cluster_IIa also had activated RTK 
and cell cycle pathways, but suppressed hormonal signaling pathways (Fig. 4b). Similarly, a 
subset of HNSC and lung samples that had EGFR levels comparable to a subset of GBM 
samples (28%) were located in cluster_IIb, warranting exploration of potential benefit from 
EGFR pathway-targeted drugs29. Tumors in cluster_IIb were enriched in EGFR mutations, 
contained few PTEN mutations, and had elevated RTK pathway and suppressed mTOR 
pathway signatures. Clusters III-VII consisted of a mixture of all tissue types. Cluster_V was 
the most distinctive, exhibiting a strong “reactive” signature5, with elevated MYH11, 
RICTOR, Caveolin1, and Collagen VI, and an activated EMT signature. Cluster_V also 
exhibited low cell cycle, Wnt-signaling and DNA damage response pathway signatures. 
Cluster_V contained the majority of the breast reactive samples along with multiple other 
tumors with a “reactive” signature consistent with the reactive phenotype being a pan-cancer 
characteristic. Cluster_III was the antithesis of “reactive” cluster_V and was primarily 
driven by elevated BRAF, ER-alpha and E-cadherin (Fig. 3b). In contrast to cluster_V, 
cluster_III had low EMT, apoptosis, and MAPK pathway signatures, but high DNA damage 
and hormonal pathway signatures. Patients in cluster_III may potentially benefit from 
(pre)clinical hormone targeting therapies. Cluster_III also had high beta-catenin levels, 
suggesting activation of the canonical Wnt-signaling pathway. Cluster_IV also had high 
beta-catenin, as well as activated AKT, MAPK and mTOR pathways, but suppressed DNA 
damage, apoptosis, EMT and cell cycle pathways. Cluster_IV and cluster_VII were 
antitheses. The high levels of phosphoAKT and phosphoMAPK in cluster_IV, suggested 
evaluation of (pre)clinical benefit from kinase-targeted therapies. Cluster_VI showed high 
EMT, cell cycle, apoptosis, mTOR and MAPK pathway signatures, also suggesting further 
evaluation of kinase-targeted therapies. Cluster_VI had low beta-catenin, consistent with 
suppressed Wnt-signaling. Cluster_VII also showed low beta-catenin, with suppressed 
AKT, MAPK, mTOR and RTK pathways.
Interestingly, clinical outcomes correlated with MC cluster membership, indicating the 
power to identify important tissue-independent processes. COAD in cluster_V had better 
outcome compared to COAD located in other clusters (Fig. 3g) (n=334), which may, in part, 
be due to depletion of mutations in TP53 (6% vs. 15%, Fisher’s Exact (FE) P = 0.05), APC 
(14% vs. 25%, FE P = 0.044) and KRAS (5% vs. 16%, FE P = 0.013), consistent with 
previous literature showing these are associated with a worse outcome30, 31, 32. The poor 
outcome for KIRC in cluster_VII may be partly due to enrichment of TP53 mutations (6% 
vs. 0.8%, FE P = 0.005, n=454) (Fig. 3c). In contrast, KIRC in cluster_IV are associated 
with better prognosis (Fig. 3e). For OVCA, membership in cluster_VII is associated with 
improved survival (Fig. 3d). LUSC in cluster_V appear to have worse prognosis, which may 
be related to elevated EMT pathway activity compared to LUSC in other clusters 
(Supplementary Fig. 5)33, 34, as well as low E-cadherin protein levels (Fig. 3f). Thus, 
reduction of tissue-specific signatures reveals a number of processes that transcend tissue 
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boundaries and may represent cross-tissue biological, prognostic, and therapeutic 
opportunities.
Analysis of pathways and targets
To capitalize on the RPPA data, we developed a series of pathway predictors (see Methods), 
based on member proteins selected by literature review (Supplementary Table 13). TSC/
mTOR signaling, which integrates information from the PI3K/Akt, Ras/MAPK and LKB1/
AMPK pathways35, was treated as a separate pathway, as was the hormone_a (ER, pER and 
PR) and a series of downstream components of the hormone signaling pathway 
(hormone_b36, 37, 38). All proteins and genomic events with a Spearman’s ρ>0.3 or ρ<−0.3 
for association with the pathway score are also presented (See methods, Fig. 4, 
Supplementary Figs.6-9, Supplementary Table 13) providing additional information on 
potential pathway membership.
In general in the RBN analysis, pathway scores were associated with tumor lineage (Fig. 4a, 
Supplementary Fig. 10). In Figures 4a,b, each cell in the heatmap represents the mean 
pathway score for that cluster or tumor lineage. Blue represents a suppressed pathway, red 
means an activated pathway, and white representing a score that does not differ across the 
set (see Methods). As expected, individual RBN clusters (Fig. 4a) show similar pathway 
scores to their dominant constituent tumor lineages, e.g. GBM is similar to cluster_H, KIRC 
is similar to cluster_G, etc. However, as clusters E and F do not consist of a single 
predominant lineage, their pathway score pattern is not concordant with any one tumor 
lineage. Similarly, the MC heatmap (Fig. 4b) shows that MC clusters, in which tissue 
specific effects are removed, do not reflect a single tumor type. This emergent phenotype 
illustrates the mitigation of tissue-specific signatures by MC, and the emergence of new, 
pan-cancer patterns that span multiple tumor types. In Supplementary Fig. 10, the data is 
transformed so that the color spectrum in the heatmaps represents absolute values of 
pathway scores (where only score magnitude is considered) and thus reflects ‘distance from 
the global pathway mean’, rather than relative protein level (see Methods). This emphasizes 
that both low (e.g. inhibitors) and high protein levels can be markers of pathway activity. 
Thus in Supplementary Fig. 10, UCEC and HNSC have a near identical hormone_a score, 
caused by a high (UCEC) and low (HNSC) protein score respectively. The pathway-based 
analyses benefit hugely from the large dataset providing sufficient power to identify 
associations that could otherwise not be robustly identified.
Focusing on individual pathway analysis (Fig. 4c-f, Supplementary Figs. 6-9), the high 
degree of correlation between pathway members, including phosphoproteins, supports the 
ability of RPPA to capture high-quality information including phosphoprotein levels from 
TCGA samples. Unexpectedly, the proteins driving the pathway signatures varied across 
individual tumors and tumor lineages, as did the associated proteins and genomic aberrations 
(Fig. 4, Supplementary Figs. 6,8). This suggests that intrinsic gene expression patterns or 
mutational patterns provide important contributions to convergent functional pathway 
output. The EMT signature, which may also represent reactive stroma, showed the greatest 
variation, being markedly elevated in GBM and reactive BRCA tumors (Fig. 4c,e). 
Significant variation in EMT was also observed within disease type and RBN clusters. For 
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example, Cluster_F (HNSC, LUAD, LUSC) showed a separation into distinct epithelial and 
mesenchymal groups based on the EMT score and related protein EMT markers. RTK and 
downstream signaling signatures were elevated in GBM, likely due to EGFR amplification 
and activation of downstream signaling events (Fig. 2). Endometrial, ovarian and most 
breast cancers demonstrated a high hormone_a signature (Fig. 4d,f). However, an elevated 
hormone_b signature, indicative of functional downstream activation, was restricted to 
luminal, reactive, and HER2-positive breast cancers (Supplementary Fig. 11) suggesting 
differential “wiring” of hormonal signaling across tumor lineages. HER2-positive breast 
cancers, whether ER-positive or -negative, demonstrated elevated levels of GATA3, 
INPP4B, and AR (hormone_b signature) suggestive of active downstream hormonal 
signaling despite low levels of ER, pER and PR in many of the HER2-positive tumors (Fig. 
2, Supplementary Fig. 11). A subset of endometrial cancers had massively elevated pAkt 
levels, likely due to the high frequency of coordinated genomic aberrations in the PI3K 
pathway, in particular, the loss/mutation of PTEN10, 39 which is consistent with 
responsiveness of endometrial cancers to PI3K pathway inhibitors40, 41.
We analyzed a number of potentially actionable proteins (n=25, Fig. 5a,b), selected based on 
a literature review (Supplementary Methods) for associations with proteomic and genomic 
events as well as for potential ability of proteomics to identify patients likely to benefit from 
targeted therapies. Luminal breast cancers (including AR-positive triple-negative breast 
cancers which cluster with luminal breast cancers) demonstrated selective elevation of AR, 
BCL2, FASN and pACC, suggesting these molecules or their associated pathways as 
potential therapeutic targets. The elevation of HER3 in KIRC may represent a therapeutic 
opportunity. SRC is activated in all but the hormone-responsive and bladder cancers, 
offering another potential therapeutic opportunity. EGFR activity, in general, parallels SRC 
activity, but in GBM is associated with NOTCH1 and HER3 activation, suggesting an 
interesting opportunity for exploration of combination therapy in (pre)clinical studies. 
PhosphoSRC, which is a downstream target of EGFR, was highly expressed in a subset of 
HNSC tumors, suggesting that these may be more sensitive to EGFR targeting strategies. As 
noted above, HER2 levels are elevated in a subset of UCEC, BLCA, BRCA and colorectal 
cancers and may represent responsiveness to HER2 targeted therapy. MYC, which may 
become targetable by emerging therapeutic approaches42, is selectively amplified and 
expressed in high-grade serous ovarian cancer and may represent an important target in this 
disease that currently lacks targeted opportunities7.
To determine whether protein levels, including phosphoproteins, can predict patient 
outcome, we determined correlations with overall survival (see TCPA11) for a 
comprehensive analysis) using Cox Proportional Hazards (CoxPH) models. In the complete 
Pan-Cancer dataset, 80 (including 24 phosphoproteins) of the 181 proteins demonstrated a 
significant (corrected for multiple comparisons) correlation with outcome. Importantly, 57 
proteins, including 19 phosphoproteins, showed a multiple comparisons corrected 
correlation with outcome in KIRC. However, with the exception of breast cancer (13 
candidates), this approach showed five or fewer proteins correlating with outcome in other 
tumor lineages. Why kidney cancer shows such strong correlations is not completely 
understood, but may reflect the maturity of the outcome data in this dataset. For some of the 
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other diseases included in the Pan-Cancer dataset, the associated outcome data are 
immature, for example, the low number of events in the BRCA and endometrial cancer 
datasets limits the ability to detect the prognostic and predictive value of protein markers.
To extend the single protein analysis available in TCPA, we performed a formal training/test 
set analysis of pathways and potentially actionable proteins. As indicated in Supplementary 
Table 14; 17 predictors (4 pathways, 9 total proteins and 4 phosphoproteins) passed a 
rigorous training/test set approach and showed a robust correlation with outcome in at least 
one disease. As expected from the analysis of single proteins, most surviving correlations 
were in kidney cancer. Several pathway predictors that survived the training/test set 
approach demonstrated marked associations with patient outcome in the overall sample sets 
(Supplementary Fig. 12). PhosphoSRC (SRCpY416) and the transferrin receptor (TFRC) 
showed an association in three diseases suggesting particular importance for outcome. 
However, the effects of the TFRC on patient outcomes were different across diseases 
suggesting an interaction with lineage-specific events. TFRC expression was associated with 
a significantly worse prognosis in LUAD and KIRC. These findings have potential 
implications for clinical targeting using TFRC for targeted delivery of chemotherapy or 
other agents43. Comparing the performance of the optimized cutoff approach with medians, 
quartiles or tertiles, more often applied in literature, we note that up to 50% of the 
predictions from the optimized cutoff approach were confirmed using these alternative 
cutoffs. However the optimized cutoff approach, combined with a rigorous training and test 
set evaluation, performed better in 17 out of 21 (81%) cases (as indicated by lower P-values) 
compared to the use of median, tertiles or quartiles.
Network visualization
Based on the availability of protein data across a large number of samples, we used a 
probabilistic graphical models approach44, 45 without the inclusion of prior knowledge to 
create an unbiased signaling network (Fig. 6, see Methods). We used the relatively large 
number of samples per tumor lineage to elucidate links in specific cancers and across 
multiple cancers, inferring networks using tumor lineage-specific samples. Interplay 
between nodes was quantified using scores from the graphical model analysis (see Methods) 
that identify links between nodes whilst controlling for the effects of all other observed 
nodes. Several expected links were observed across most tumor types, including pMEK with 
pERK, beta-catenin with E-cadherin and pPKCdelta with pPKCalpha and pPKCbeta, 
supporting the ability of RPPA analysis to yield high-quality signaling information from 
TCGA samples. Other expected links were seen in only a subset of tumors such as pAKT 
with pPRAS40 and pTSC2 (tuberinPT1462), consistent with differential wiring of signaling 
pathways in different cancers. A number of other links such as MYH11 with Rictor, cyclinB1 
with FOXM1, and pACC with FASN were not expected and warrant further exploration. The 
interplay between p85 and PTEN is consistent with our demonstration that p85 is a key 
determinant of PTEN stability39, 46. The negative link between pAKT and PTEN was 
expected, but the one between p85 and claudin7 in LUSC was not and may be worthy of 
further exploration. PI3K/AKT signaling does not link clearly to mTOR, which appears to 
primarily be downstream of MAPK signaling47, 48, 49. The relatively weak links in the 
PIK3K/AKT pathway are striking given the degree of antibody representation for this 
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pathway in the RPPA analysis. Key nodes such as CDK1 unexpectedly linked a wide range 
of protein pathways. Overall, the data suggest that the EGFR receptor family, together with 
the linked MEK and MAPK pathways, is the dominant determinant of signaling across the 
cancer lineages in the Pan-Cancer analysis. Using independent datasets in breast cancer, 
ovarian cancer and endometrial cancer, as well as published research, many of the strongest 
protein links in the network could be validated (Supplementary Fig. 13 and Supplementary 
Table 15), supporting the notion that large RPPA-based protein datasets can be used to 
“learn” networks in an unbiased manner.
Discussion
Cellular biology is effectuated in considerable part by proteins, and, unfortunately neither 
DNA copy number nor mRNA expression are able to faithfully predict protein level and in 
particular the post-translational modifications of proteins that are necessary for function 
(Fig. 1, Supplementary Fig. 1)1, 2, 3, 50, 51. Hence, evaluation of the functional proteome 
offers the ability to complement genomic and transcriptomic analysis in projects like the 
TCGA for identification of biomarkers and elucidation of underlying biological mechanisms 
both within and across diseases. The availability of high-quality proteomic data across large 
numbers of samples makes the case more compelling. In sum, a proteomic view of TCGA 
data yields insights that cannot be acquired through analysis driven solely by genomics or 
transcriptomics. The high degree of correlation between proteins, including 
phosphoproteins, in signaling pathways (Figs. 2,4,6, TCPA11) supports the applicability of 
RPPA analysis to TCGA samples. Further, the ability to construct de novo signaling 
networks (Fig. 6) that capture many known relationships supports the contention that 
proteomic data derived from the RPPA analysis of TCGA samples can be used to inform 
systems-level analyses of signaling pathways and networks. Full integrative analysis of the 
DNA, RNA and protein relationships embodied in the several TCGA datasets will require 
additional analysis, but a number of interesting observations are immediately apparent.
Analysis of this large dataset demonstrates that, in general, tumor type and subtype are the 
dominant determinants of protein levels. This observation highlights the risk inherent in 
disease-specific studies that commonalities, differences, and themes that emerge across 
tumor types will remain undiscovered. We therefore implemented a computational 
approach, MC, to decrease the dominant effect of tissue-specific protein expression. This 
approach allowed for the discovery of processes that drive cellular behavior across tumor 
types and made it possible to identify tumor characteristics that warrant exploration as 
therapeutic opportunities. The analysis of individual therapeutically relevant proteins (e.g., 
HER2, Figs. 1,5) and pathways (Fig. 4) permitted classification of patient samples based on 
pathway activity and therapeutic tractability across different tumor types. The ability of the 
Pan-Cancer analysis to identify the discordance between HER2 CNV, mRNA expression 
and protein expression in colorectal and serous endometrial cancers (Fig. 1) argues that a 
broad protein-based analysis of patient samples across multiple diseases can highlight 
potential therapeutic opportunities not obvious from studies within single diseases or driven 
by RNA and DNA analysis alone.
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The pathway analysis (Fig. 4, Supplementary Figs. 6-9) identifies multiple protein changes 
that are associated with the same functional outcome (i.e., pathway activation) in different 
samples and tumor types (Fig. 4). A number of proteins and genomic events correlate with 
pathway scores, developed using proteins defined by literature review (Fig. 4). Although 
some of those relationships could be identified by including members of upstream or 
downstream signaling or interacting pathways, many of the associations would not be 
predicted a priori, demonstrating that these approaches offer the potential for discovery of 
novel pathway connections. The ability to identify unexpected correlations was particularly 
clear in the network analysis (Fig. 6). For example, the strong links between MYH11 and 
RICTOR and between ETS1 and pPEA15 across tumor types offer opportunities for 
discovering new functional relationships. Some associations we reported, such as that of the 
mTOR pathway with MEK and MAPK, while supported by the literature47, 48, 49, 52 do not 
currently receive adequate consideration. Although molecular pathways often seem “set in 
stone”, the identification of unbiased signaling networks using large datasets can provide a 
powerful tool to identify tissue-specific networks, as well as to demonstrate the importance 
of “non-canonical” interplay, allowing for re-conceptualization of networks and the role 
they play in specific diseases.
A major goal of the molecular characterization of tumors, is the identification of tumor 
subsets and specific aberrations that can be used in the clinic as biomarkers and/or for 
targeted therapy (either single-agent or in combination). A bird’s eye view of the functional 
proteome of large sample sets encompassing multiple tumor lineages may help to suggest 
potential unexpected targets that are applicable to disease subsets or across diseases. The 
ability to identify many biomarkers associated with patient outcome (TCPA) and the ability 
of a set of biomarkers to pass a rigorous training/test set approach (Supplementary Table 14) 
suggest that additional Pan-Cancer analyses, as well as mechanistic analyses of the current 
proteomics study will improve our ability to understand tumorigenesis and identify new 
markers and targets.
Methods
Description of the protein data
Proteomic data were generated by RPPA across 3,467 patient tumors obtained from TCGA, 
including 747 breast (BRCA), 464 colon and rectal adenocarcinoma (COAD and READ), 
454 renal clear cell carcinoma (KIRC), 412 high-grade serous ovarian cystadenocarcinoma 
(OVCA), 404 uterine corpus endometrial carcinoma (UCEC), 237 lung adenocarcinoma 
(LUAD), 212 head and neck squamous cell carcinoma (HNSC), 195 lung squamous cell 
carcinoma (LUSC), 127 bladder urothelial carcinoma (BLCA) and 215 glioblastoma 
multiforme (GBM). Those were all the samples we could obtain from TCGA and no 
samples were excluded. The result is, to our knowledge, the largest and most diversified 
database of tissue protein levels yet available, an unparalleled basis for rich functional 
analysis.
RPPA methodology has been described in 4, 5, 6, 7, 8, 9, 10 and is also provided in the 
Supplementary Methods. In total 181 high-quality antibodies targeting total (n=128), 
cleaved (n=1), acetylated (n=1) and phosphoproteins (n=51) were used (detailed in 
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Supplementary Data 9). In the RPPA assay, antibodies to phosphoHER2 and phosphoEGFR 
have been noticed to cross-react, especially when the opposite molecule is present at very 
high levels. This mainly concerns EGFRpY1068 (but not EGFRpY1173), which cross-reacts 
with overexpressed HER2pY1248. Taking into account their favorable signal:noise ratio 
(10:1), useful information is contributed by both if expressed differentially, and they are thus 
both included. The antibodies encompass major functional and signaling pathways of 
relevance to human cancer. Pathways included are proliferation, DNA damage, polarity, 
vesicle function, EMT, invasiveness, hormone signaling, apoptosis, immunological, stromal, 
TGFα/β, transmembrane receptors, metabolism, LKB1/AMPK, TSC/mTOR, PI3K/Akt, 
Ras/MAPK, Hippo, Notch, and Wnt/beta-catenin signaling (Supplementary Fig. 14 and Fig. 
6) with minimal redundant information (Supplementary Fig. 15). Supplementary Fig. 16 
shows a representative image of a typical antibody slide.
The numbers of patient samples and antibodies are greater than those presented in previous 
TCGA marker papers4, 5, 6, 7, 8, 9, 10 based on the availability of additional samples as well 
as validation of additional antibodies. The detailed TCGA datasets are available online 
(https://tcga-data.nci.nih.gov/tcga) and combined with a number of visualization and 
analytic tools from TCPA (http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/
index.html). High-resolution images of all heatmaps and the network are available online 
(http://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA). Some key clinical 
variables are shown in Supplementary Tables 16-17; extensive clinical information for all 
lineages is available online (https://tcga-data.nci.nih.gov/tcga) and available in the various 
TCGA marker papers4, 5, 6, 7, 8, 9, 10.
Protein correlations
To match the 181 antibodies available, 162 unique mRNAs were selected from downloaded 
RNASeqV2 data (https://tcga-data.nci.nih.gov/tcga), resulting in 184 matched and 24,282 
random protein:mRNA pairs. Spearman’s rank correlations were computed on both the 
random and matched pairs, with associated P-values (Supplementary Data 1,2 and at http://
bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA). The ρ values of the matched 
pairs were plotted in histogram form; the ρ values of the random pairs are represented as a 
background curve (Fig. 1a, Supplementary Fig. 1). Student’s t-test was used to compare the 
ρ values of all matched pairs with the ρ values of all random pairs (mean matched pairs: 0.3; 
mean random pairs: −0.006) and showed a significant difference (P<2.2e-16). For miRNA 
vs. protein, because the number of miRNAs and proteins were small, we computed all pair-
wise Spearman’s rank correlations with t-test P-values (Supplementary Data 3). For the 
CNV vs. protein expression analysis, we divided the samples into groups of amplified vs. 
copy number neutral and deleted vs. copy number neutral, and computed the mean fold 
changes in protein expression. Similarly, to compare mutation vs. protein, we divided the 
samples into mutated vs. wildtype and computed the fold changes in protein expression. We 
then used t-tests to evaluate statistical significance of the fold changes (Supplementary Data 
5-8 and at ttp://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA
Furthermore, we computed all pair-wise protein:protein correlations using the entire Pan-
Cancer dataset, in total 16,290 correlations (Supplementary Data 4 and at http://
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bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA). The top-10% had a 
Spearman’s rank correlation coefficient magnitude of 0.3 or higher (Bonferroni-adjusted 
P≤3.67e-67). Consequently, we considered a correlation magnitude of 0.3 or higher (sign 
independent) as a reasonable cutoff threshold for the analysis presented in the pathway 
sections of this study (Fig. 4, Supplementary Figs. 6-10, Supplementary Table 13).
Discriminator selection
To detect the discriminating biomarkers for each cluster (obtained by hierarchical clustering 
using the RPPA data normalized by either RBN or MC), LIMMA53 was used for the 
continuous data (protein, mRNA, miRNA) by comparing samples in each cluster with 
samples in all the other clusters together; information gain54 was used to select the 
categorical discriminators (mutation). The resulting data were sorted by decreasing order of 
the log-odds for the former and by decreasing information gain for the latter method. The 
top-25 most significant discriminators are shown in Supplementary Tables 2-5 (RBN) and 
Supplementary Tables 9-12(MC). The complete overview of protein, mRNA, miRNA and 
mutation discriminators can be accessed online (http://bioinformatics.mdanderson.org/main/
TCGA/Pancan11/RPPA).
BRCA and UCEC subdivision
For BRCA subtypes, first the reactive subtypes were classified according to the method 
described in the TCGA marker paper5. The other subtypes were then classified based on 
PAM50. For UCEC subtype classification, serous samples were first selected based on the 
integrative cluster (serous-like) reported in the TCGA marker paper10. Clinical 
histopathological subtype (https://tcga-data.nci.nih.gov/tcga) was used in any remaining 
cases.
HER2 cutoffs
Normal tissues for the lineages studied in this paper have been reported to have low or 
medium HER2 levels (http://www.proteinatlas.org/ENSG00000141736/tissue/staining
+overview)55. To identify the threshold of HER2 mRNA and protein expression in breast 
cancer that could classify tumors as HER2-positive, we obtained PAM50 classifications for 
all the TCGA breast cancer samples, and divided them into two groups; HER2-positive and 
non-HER2-positive samples. We used the conjunctive rule algorithm in Weka software56 to 
determine the best HER2 total protein cutoff that separated the HER2-positive from the non- 
HER2-positive samples based on HER2 (ERBB2) copy number. The best protein threshold 
was found to be 1.46, which yielded 93% accuracy of prediction and a receiver operator 
characteristic (ROC) area under the curve (AUC) of 0.81. We did a similar analysis using 
HER2 mRNA and found a best cutoff of 14.26 (in log2 frame), which yielded an accuracy of 
93% and a ROC AUC of 0.82. In addition to trastuzumab, other drugs targeting HER2 have 
entered clinical trials, such as TDM1, for which HER2 expression on the cell surface is 
sufficient to achieve preferential binding to the cell and therapeutic impact. Since data for 
TDM1 response is not readily available, a threshold of HER2 expression that may be 
sufficient to expect a response could not be calculated. We therefore compared samples in 
which HER2 was amplified vs. not amplified, aiming to find a threshold that might be 
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reasonable to test. Using the dot plots, a protein threshold of ≥1.00 was adopted; roughly 
equivalent to 3+ on immunohistochemistry of clinical samples in breast cancer. The crosstab 
in Figure 1b gives the breakdown of percentage of samples above these thresholds for each 
tumor. If a tumor lineage had more than 5% HER2-positive samples according to any of the 
cutoffs, this is indicated in red.
General heatmap section
A two-way unsupervised hierarchical clustering analysis was used to discover the groups of 
biological objects sharing common characteristics57, 58, and a two-dimensional heat map 
was drawn to visualize protein expression patterns. We used Ward linkage as the 
agglomeration rule and 1-Pearson correlation as the dissimilarity metric. Based on protein 
expression patterns and guided by the clustering dendrogram, we divided the RBN data set 
into 8 clusters and the MC dendrogram into 7 clusters. As seen in the RBN heatmap, most 
clusters represented one major disease. Exceptions were clusters_E and _F. Based on the 
recent TCGA marker paper5, the hormone-responsive breast cancer cluster (cluster_A) in 
the RBN dendrogram was further divided into 2 subclusters, A1 (reactive breast cancers) 
and A2 (remaining luminal breast cancers). Based on marked enrichment with clinically 
relevant proteins, cluster_II in the MC dendrogram was further divided into two subclusters, 
cluster_IIa (HER2 elevated) and cluster_IIb (EGFR elevated). Hierarchical clustering 
analysis was performed using R, version 2.15.1 (http://www.r-project.org/). Heatmaps were 
generated using an NGCHM R-package59. Annotation bars were added to the heatmap that 
included tumor lineage, purity and ploidy; stromal and immune scores; BLCA subtype and 
PAM50 classification (BRCA). Significantly mutated genes (present in more than 5% of 
tumors in the dataset, resulting in 16 genes) are included as are the two most frequently 
observed amplifications. Statistical significance for the annotation bars on top of the various 
heatmaps was calculated by Chi-squared test (tumor lineage, mutations and amplifications), 
ANOVA’s F test (purity, ploidy stromal and immune score), and Fisher’s exact test (PAM50 
and BLCA subtypes). Data are missing for BLCA subtype (15/127), BRCA subtype 
(52/747) and HER2 and MYC amplification (64/3,467).
Batch effects removal
The 3,467 RPPA Pan-Cancer samples were run in 6 batches in total, resulting in potential 
batch effects upon merging the sets. Batch effects in RPPA data are a known concern, even 
when controlling for critical materials such as the treated glass slides, antibodies, enzymes 
and suppliers60. A new algorithm, replicates-based normalization (RBN), was therefore 
developed, using replicate samples run across multiple batches to adjust the data for batch 
effects. The underlying hypothesis is that any observed variation between replicates in 
different batches is primarily due to linear batch effects plus a component due to random 
noise. Given a sufficiently large number of replicates, the random noise is expected to 
cancel out (mean=zero by definition). Remaining differences are treated as systematic batch 
effects. We can compute those effects for each antibody and subtract them out. In one batch, 
many samples with duplicates in the other 5 batches were run, and could therefore serve as 
anchor for all batches. The number of duplicate samples with each batch varied between 71 
and 207. This batch was designated “anchor” batch and was used unchanged. We then 
computed the means and standard deviations of the common samples in the anchor batch 
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and each of the other batches. The difference between the means of each antibody in the two 
batches and the ratio of the standard deviations provided an estimate of the systematic 
effects between the batches for that antibody (both location-wise and scale-wise). Each data 
point in the non-anchor batch was adjusted by subtracting the difference in means and 
multiplying by the inverse ratio of the standard deviations to cancel out those systematic 
differences. Whether RBN could successfully integrate batches while preserving known 
biological variation, was tested on TCGA breast cancer samples. As breast cancer subtypes 
(luminal, HER2-positive and basal-like) are well established13, we expected the subtypes 
from different batches to cluster together. Without RBN, the batches clustered by batch. 
After RBN, the batches clustered by subtypes spanning multiple batches (Fig. 2). Details of 
these experiments have been published previously61.
Reducing tissue differences to cluster across tumors
Using RBN, batches of RPPA data could be merged successfully. However, as protein levels 
of different tumors are (usually) quite distinct from each other, most samples clustered by 
tumor lineage (Fig. 2). Normal cells differentiate into different tissues by turning on or off 
different sets of genes. When cells become malignant, they retain many tissue-specific 
expression characteristics. We hypothesized that tissue-specific effects exist because of 
those expression differences and equalizing the median expression of genes across tumors 
might reduce those effects. A gene that is turned off in all the samples of a tumor lineage 
will have little variation in expression, similar to a gene that is always turned on, which will 
also have little variation, but an overall high level. To compare across tumor lineages, we 
started with the batch corrected RBN data and took sets of all samples belonging to each 
tumor lineage. We subtracted the median protein expression across all the samples from a 
single lineage (median centering, MC), making the median expression of all proteins within 
any given tumor equal to zero. That removed the fixed, bias component from that tissue 
lineage but retained the variable component found in each tumor. Since the tissue specific 
component had been removed, we could then compare the variable component (which was 
relative in scale) in each tumor sample across different tissues. That allowed for the 
comparison between samples with high/low expression in one tumor and samples with 
high/low expression in another tumor, such as HER2 or EGFR expression. Basal-like breast 
cancer was treated as a separate tumor lineage from the other breast cancer samples due to 
its expression profile being so different that it did not merge with any other tumor or even 
other breast samples during RBN clustering.
Tumor purity and ploidy
We obtained tumor purity and ploidy data based on the ABSOLUTE algorithm62 from 
TCGA Pan-Cancer working group. We calculated stromal and immune scores based on the 
ESTIMATE algorithm using the TCGA Pan-Cancer gene expression dataset (syn1695373, 
https://www.synapse.org/#!Synapse:syn1695373 63).
Pathway analysis
For each pathway, members, illustrated in Supplementary Table 13, were predefined based 
on a Pubmed literature search on review articles describing the various pathways in detail. 
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RBN RPPA data were median-centered and normalized by standard deviation across all 
samples for each component to obtain the relative protein level. The pathway score is then 
the sum of the relative protein level of all positive regulatory components minus that of 
negative regulatory components in a particular pathway. We averaged antibodies targeting 
different phosphorylated forms of the same protein with ρ >0.85 (Pearson’s correlation). The 
pathway scores are visualized in the bar just above the heatmap and as a dotplot below the 
heatmap (median and inter-quartile range indicated, Fig. 4c-f, Supplementary Figs. 6-9). 
Subsequently, for each version of the pathway scores (RBN or MC derived), a Spearman’s 
rank correlation test was performed between each pathway score and every protein. If the ρ 
was >0.3 or <−0.3, the protein was included in the heatmap. Regardless of the ρ, pathway 
members for the given pathways were included. Annotation bars (from Fig. 2) were included 
if they were statistically significantly associated with the pathway (P<0.05, Kruskal-Wallis 
test, n=3,467), corrected for multiple testing64. Tumor lineage and cluster were included to 
facilitate interpretation. For each pathway heatmap (RBN or MC), the samples were first 
sorted by the alphabetic order of either cluster or tumor, and then by the increasing order of 
a pathway score.
Using the heatmap method described above, two additional summary heat maps for the 
pathway scores (RBN and MC) were generated (Fig. 4a,b) to provide an overall view of the 
relationships between tumors, unsupervised clusters and pathways. Mean pathway scores 
were calculated for each tumor as well as cluster variables, and the combined mean pathway 
scores were standardized for each pathway across all tumor and clusters. In both the 
individual pathway plots and the heatmap summary plots, hierarchical clustering was based 
on Pearson’s correlation-based distance matrices65 and Ward linkage. The dynamic heat 
maps were generated using the R-package NGCHM59. Each cell in the heatmap represents 
the mean pathway score of all the samples in that cluster or tumor lineage, with blue 
representing a suppressed pathway, red representing an activated pathway, and white 
representing neither.
Supplementary Figure 10a,b shows a similar measure of pathway activity, but on the 
absolute scale. The supplementary figure is derived as follows. First, the RPPA dataset 
(either RBN or MC normalized) is globally scaled so that the protein expression level 
measurements have zero mean and unit standard deviation over all samples. Next, for each 
cluster and tumor lineage, we calculate the mean (scaled) protein expression level for each 
protein. We then convert these means to their absolute value (as low or high mean protein 
levels could both be markers of pathway activity), obtaining an absolute mean protein level 
for each protein in each cluster or tumor lineage. Finally, for each pathway, we calculate the 
average of the absolute mean levels over the proteins that participate in the pathway. This 
value is designated the differential pathway activity score, as it indicates the deviation from 
the mean expression of a pathway in a given cluster or tumor lineage, and can thus be seen 
as a proxy for pathway activation/deactivation.
Actionable protein analysis
The analysis focused on the potential ability of proteomics to predict response to proteins 
currently of increased interest, due to proposed targetability or potentiality as a drug target in 
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the drug development stage. The list of proteins is not exhaustive, but rather includes many 
different processes and pathways with varying importance in different tumor lineages 
included in this study. In the Supplementary Methods, registered trials targeting many of 
these proteins are included.
To visualize the expression pattern of these 25 proteins, heatmaps were generated59 using 
the RBN dataset (Fig. 5). Proteins were ordered by unsupervised hierarchical clustering and 
samples were ordered by cluster (disease) membership and within each, ordered by 
unsupervised hierarchical clustering. Ward’s method and 1-Pearson correlation were used as 
a dissimilarity metric and linkage.
Network analysis
Networks were estimated using statistical models known as a probabilistic graphical models 
(specifically Gaussian graphical models)45. These models use an undirected graph or 
network to describe probabilistic relationships between variables. In contrast to pair-wise 
correlation analysis, the networks are rooted in a global, multi-dimensional approach that 
identifies links between nodes whilst controlling for the effects of all other observed nodes.
Statistical inference of networks is a so-called ‘high-dimensional’ problem because network 
descriptions require a large number of parameters relative to available sample sizes 
(especially at the disease or cluster level). This motivates a need for regularization to learn 
sparse, parsimonious networks and thereby control over-fitting. We used l1-penalization for 
this purpose, specifically via an algorithm known as graphical lasso44, as implemented in the 
R-package huge66. A parameter λ that controls the strength of penalization was set by 10-
fold cross-validation in all cases. To prevent artifacts that can arise due to duplicated nodes, 
related nodes that were relatively highly correlated were merged prior to network analysis. 
In each such case, only one of the set of correlated nodes was used for network inference 
and the remaining merged nodes are shown in white. Since protein levels are measured in 
arbitrary units (depending on affinity and avidity of specific antibodies), for each network 
the data were standardized before applying the graphical lasso, such that each protein had 
zero mean and unit variance.
Outcome analysis
A training-test approach was adopted for survival analysis. In each of the 11 tumor lineages, 
samples with survival data available were randomly divided into training (2/3) and test (1/3) 
sets with balanced events in both sets. The training set was used to obtain an optimized 
cutoff, which was “locked” (i.e. used without change) on the test set. Essentially, samples 
were sorted based on the protein expression of the interesting gene or pathway score. Each 
possible cutoff in the middle 60% of samples was checked using Cox’s regression model. 
The cutoff with lowest P-value was chosen as the optimized cutoff. In the test set, samples 
were divided into high and low groups according to this optimized cutoff by either 
percentage or absolute value. Then the hazard ratio, Wald’s test P-value and Kaplan-Meier 
survival curves of the two groups were examined by Cox’s regression analysis. Only the 
predictors that were successfully validated in the test set are shown in Supplementary Table 
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14 Kaplan–Meier survival curves were generated to illustrate the survival differences in the 
four significant pathways using the whole sample set (Supplementary Fig. 12).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. HER2 RPPA correlations with copy number and mRNA
a Histogram of Spearman’s rank correlation (ρ values) for 206 pairs of proteins and matched 
mRNAs across all tumor types. The black curve represents the background of ρ values using 
28,960 random protein-mRNA pairs in the same dataset.
b Crosstab identifying HER2-positive tumors by copy number, mRNA expression and 
protein expression across 11 tumor types. Cutoffs are defined in Methods. BRCA and UCEC 
are subdivided for clinical relevance regarding HER2 protein levels. Total sample numbers 
with analyses for all three platforms (CNV, mRNA and protein) are indicated in parentheses. 
Percentages ≥5% are highlighted (red).
c Relationship between HER2 copy number and HER2 protein level by RPPA across all 
tumor types (n=2,479). The box represents the lower quartile, median and upper quartile, 
whereas the whiskers represent the most extreme data point within 1.5 × interquartile range 
from the edge of the box. Each point represents a sample, color-coded by tumor type or 
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subtype. As expected, ERBB2 amplified samples have much higher HER2 protein levels 
than non-amplified samples.
d Relationship between HER2 mRNA and protein expression across all tumor types 
(n=2,479). Each protein represents a sample, color-coded by tumor type or subtype. 
Spearman’s correlation between HER2 protein and mRNA is 0.53.
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Figure 2. Unsupervised clustering and analyses based on the RBN dataset
a Heatmap depicting protein levels after unsupervised hierarchical clustering of the RBN 
dataset consisting of 3,467 cancer samples across 11 tumor types and 181 antibodies. Protein 
levels are indicated on a low-to-high scale (blue-white-red). Eight clusters are defined. 
Cluster_A has been subdivided into two clusters (A1 and A2), based on the differences 
between BRCA reactive and remaining luminal subtypes5. Annotation bars include tumor 
type (BRCA-basal separately indicated); purity and ploidy (ABSOLUTE algorithm); stromal 
and immune scores (ESTIMATE algorithm); BRCA (PAM50 classification) and BLCA 
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subtype; 16 significantly mutated genes and two frequently observed amplifications. The 
statistical significance of correlations between the clusters and each variable is indicated to 
the left of each annotation bar (n=3,467, chi-squared, Fisher’s Exact, and ANOVA’s F test. 
See Methods).
b Crosstab showing the number of tumor samples in each cluster.
c-e Kaplan Meier curves showing overall survival of (c) the BRCA located in four separate 
clusters (A1, A2, E and F, n=740), (d) KIRC in cluster_F vs. KIRC in other clusters (n=454) 
and (e) BLCA in cluster_B vs. BLCA in other clusters (n=127). Follow-up was capped at 60 
months due to limited number of events beyond this time. Statistical difference in outcome 
between groups is indicated by P-value (log-rank test). A high-resolution, interactive version 
of the heatmap with zooming capability, can be found at (http://
bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
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Figure 3. Unsupervised clustering and analyses based on the MC dataset
a Heatmap showing protein expression after unsupervised hierarchical clustering of 3,467 
cancer samples across 11 tumor types and 181 antibodies. Protein levels are indicated on a 
low-to-high scale (blue-white-red). Seven clusters were defined. Cluster_II has been 
subdivided manually into two clusters (IIa and IIb) based on significant difference in 
expression of the proteins of interest (HER2 and EGFR). Annotation bars include tumor 
lineage (BRCA-basal separately indicated), purity and ploidy (ABSOLUTE algorithm); 
stromal and immune scores (ESTIMATE algorithm); BRCA (PAM50 classification) and 
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BLCA subtype; 16 significantly mutated genes and two frequently observed amplifications. 
Statistical significance of the correlations between the clusters and each variable is indicated 
left of the annotation bars (n=3,467, chi-squared, Fisher’s Exact, and ANOVA’s F test. See 
Methods).
b Crosstab showing the number of tumor samples in each cluster.
c-g Kaplan Meier curves showing overall survival in (c) the KIRC in cluster_VII vs. in all 
other clusters (n=454), (d) OVCA in cluster_VII vs. in all other clusters (n=412), (e) KIRC 
in cluster_IV vs. in all other clusters (n=454), (f) LUSC in cluster_V vs. in all other clusters 
(n=195) and (g) COAD in cluster_V vs. in all other clusters (n=334). Follow-up has been 
capped at 60 months months, due to limited number of events beyond this time. Statistical 
difference in outcome between groups is indicated by P-value (log-rank test). A high-
resolution, interactive version of the heatmap with zooming capability, can be found at 
(http://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
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Figure 4. Pathway analyses
Pathway analyses of the dataset by RBN clusters, MC clusters and tumor type. For pathway 
predictor members see Supplementary Table 13.
a-b Heatmaps depicting mean pathway scores after unsupervised hierarchical clustering on 
tumor lineages and protein clusters based on the (a) RBN and (b) MC datasets. The 
heatmaps were clustered on both axes. As expected, RBN clusters show a strong association 
with tumor lineages, with very similar patterns between them, whereas MC clusters do not 
associate with any particular tumor lineage.
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c-f The heatmaps, supervised on the sample axis, depict the protein levels of the pathway 
members and of proteins with a high correlation (ρ>0.3/ ρ<−0.3, Spearman’s correlation) to 
the pathway predictor across RBN clusters (c-d) and tumor lineages (e-f). The EMT 
pathway (c and e) and the hormone_a pathway (d and f) are shown. Samples are first sorted 
by either cluster (c-d) or tumor lineage (e-f), then by pathway score (from low to high) 
within cluster or tumor lineage. Dotplots (lower panel) represent the pathway score for each 
sample. Each box represents the lower quartile, median and upper quartile, whereas the 
whiskers represent the most extreme data point within 1.5 × inter-quartile range from the 
edge of the box. Annotation bars (selected from Fig. 2) are included if statistically 
associated with the pathway score (P <0.05, Kruskal-Wallis test, n=3,467). Pathway 
members are marked in red on the left hand side. High-resolution images of the heatmaps 
can be found online (http://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
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Figure 5. Analyses of selected potentially actionable proteins
a-b Heatmaps, supervised on the sample axis, depicting protein level of 25 proteins that are 
(potentially) actionable based on the RBN dataset. Proteins were ordered by unsupervised 
hierarchical clustering and samples were ordered by (a) cluster and (b) tumor lineage 
membership and within each ordered by unsupervised hierarchical clustering. Annotation 
bars include tumor lineage, purity and ploidy (ABSOLUTE algorithm); stromal and immune 
scores (ESTIMATE algorithm); BRCA (PAM50 classification) and BLCA subtype; 16 
significantly mutated genes and two frequently observed amplifications. High-resolution 
images of the heatmaps can be found online (http://bioinformatics.mdanderson.org/main/
TCGA/Pancan11/RPPA).
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Figure 6. Unbiased data-driven signaling network
Unbiased signaling network based on a probabilistic graphical models analysis, visualizing 
all 11 tumor lineages individually. Interplay between nodes was quantified using scores 
from the graphical model analysis (see Methods), that identify links between nodes whilst 
controlling for the effects of all other observed nodes. The strength of links is indicated by 
the thickness of the line whilst the color indicates the tumor lineage in which the link was 
observed; only the strongest links are shown. Nodes in white are related nodes that were 
highly correlated and therefore merged prior to network analysis. The adjacent correlated 
(green) node was then used for network generation. Positive (negative) correlations are 
indicated with continuous (dotted) lines. A high-resolution image of the network can be 
found online (http://bioinformatics.mdanderson.org/main/TCGA/Pancan11/RPPA).
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